Source link : https://www.newshealth.biz/health-news/nonsteroidal-mra-improves-outcomes-in-hfpef-hfmref/
LONDON — The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) improved outcomes driven by soft endpoints in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF, HFpEF), the FINEARTS-HF trial showed. The drug reduced by 16% the composite risk of urgent or unplanned heart failure care and death from cardiovascular causes (rate […]
Author : News Health
Publish date : 2024-09-01 19:45:02
Copyright for syndicated content belongs to the linked Source.